NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds ("PsyLabs") has exercised its rights under a previously disclosed put option agreement (the "Put Option Agreement"), pursuant to which Psyence BioMed wi ...

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, ...

At 7:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading high ...

Core Viewpoint - Psyence Biomedical Ltd. has entered into a Put Option Agreement with PsyLabs, positioning the company for significant future equity participation in a leading manufacturer of pharmaceutical-grade psychedelics, ensuring a reliable supply as commercialization progresses [1][3]. Group 1: Put Option Agreement Details - The Put Option Agreement allows PsyLabs to require Psyence BioMed to make further equity investments through a share-for-share exchange at fair market value, forming part of a broader strategic relationship [2][4]. - This agreement provides Psyence BioMed with a structured opportunity to acquire a significant equity stake in PsyLabs while securing a reliable supply of pharmaceutical-grade psychedelics for future clinical programs [3][4]. Group 2: Strategic and Commercial Benefits - The agreement enhances Psyence BioMed's clinical development pathway by mitigating supply-chain and regulatory risks, allowing the company to maintain financial flexibility without significant upfront capital deployment [4][5]. - PsyLabs is recognized as one of the most advanced manufacturers of pharmaceutical-grade psychedelic compounds, with expertise in scalable, GMP-compliant production [3][6]. Group 3: Company Background - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies to address unmet mental health needs, being the first of its kind listed on Nasdaq [8]. - PsyLabs is federally licensed to cultivate and export various psychedelic compounds, including psilocybin and ibogaine, to legal medical and research markets, with successful exports to multiple countries [6][7].

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS"). The claim, originally made on January 14, 2026, and amplified on January 26, 2026, alleged, among other things, improper and oppressive actions on the part of the Company against KAOS, resulting in KAOS suffering alleged damages (the "KAOS Allegations"). Th ...

Core Viewpoint - Psyence Biomedical Ltd. has adjourned its annual and special meeting of shareholders to February 12, 2026, due to not achieving the required quorum [1][2] Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, particularly nature-derived psilocybin and ibogaine [3] - The company is the first life sciences biotechnology firm focused on developing non-synthetic psychedelic medicine to be listed on Nasdaq, aiming to address unmet mental health needs [3] Meeting Details - The adjourned meeting will take place on February 12, 2026, at 9:00 a.m. New York Time/4:00 p.m. Cape Town time at Venture Workspace Riverlands, Cape Town, South Africa [1] - The record date for the meeting remains unchanged, set at the close of business on December 23, 2025 [2]

Core Viewpoint - Psyence Biomedical Ltd. (NASDAQ:PBM) is currently in the spotlight due to its planned reverse stock split, which aims to increase the stock price and attract investors [1] Group 1: Reverse Stock Split - PBM initially announced a reverse stock split at a ratio of 1-for-6.25, set to take effect on January 20, 2026, but has postponed this action [2][6] - The company plans to announce a new date for the reverse stock split in the future, and until then, the stock will continue trading under the symbol "PBM" without adjustments [2] Group 2: Stock Performance - Currently, PBM's stock is priced at $0.67, with a market capitalization of approximately $478,000 [3] - The stock has experienced significant volatility, with a 52-week high of $108.59 and a low of $0.615 [3][6] - The company's price-to-earnings (P/E) ratio is 0.17, indicating that the stock is trading at a low price relative to its earnings [3] Group 3: Analyst Ratings - Analysts maintain a cautious outlook on PBM, with Weiss Ratings reaffirming a "sell (e+)" rating and the consensus rating also being "Sell" [4][6] Group 4: Trading Activity - PBM's trading volume on the Nasdaq exchange is 506,821 shares, indicating active trading [5] - The stock's 50-day moving average is $1.48, while the 200-day moving average is $3.18, reflecting a downward trend over the past year [5] - The company's beta of 0.32 suggests that the stock is less volatile compared to the overall market [5]

Core Viewpoint - Psyence Biomedical Ltd. has decided to postpone the effective date of its previously announced reverse stock split of its common stock, which was initially set for January 20, 2026 [1][2]. Company Announcement - The Board of Directors had approved a reverse stock split at a ratio of 1-for-6.25, but after further internal consideration, the effectiveness of this split has been delayed to a later date [2]. - A subsequent press release will be issued, and required notifications will be filed with Nasdaq before establishing a new effective date for the reverse stock split [3]. Trading Information - Until a new effective date is established, the Company's common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "PBM" and its current CUSIP 74449F308 [3]. Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine-based medicines [4]. - The company aims to address unmet mental health needs and is committed to developing safe, effective, and FDA-approved nature-derived psychedelic treatments for various mental health disorders [4].

Core Viewpoint - Psyence Biomedical Ltd. has decided to postpone the effective date of its previously announced reverse stock split of its common stock, which was initially set for January 20, 2026 [1][2]. Group 1: Reverse Stock Split Details - The Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to take effect at the market opening on January 20, 2026 [2]. - The Company will issue a subsequent press release and file required notifications with Nasdaq before establishing a new effective date for the reverse stock split [3]. - Until a new effective date is set, the Company's common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "PBM" and its current CUSIP [3]. Group 2: Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics [4]. - It is the first life sciences biotechnology company focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq [4]. - The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for various mental health disorders [4].

Core Viewpoint - Psyence Biomedical Ltd. has announced a 1-for-6.25 share consolidation, effective January 20, 2026, following prior approvals for share consolidations at different ratios [1][2][3]. Group 1: Share Consolidation Details - The share consolidation will combine every 6.25 issued and outstanding shares into one common share, resulting in a total of 1,022,177 common shares outstanding post-consolidation [3]. - The consolidation was approved by shareholders at a Special Meeting on April 16, 2025, allowing the Board of Directors to implement a consolidation ratio of up to 1-for-50 [1]. - The Company had previously authorized a 1-for-7.97 consolidation ratio, which was implemented on May 5, 2025 [1]. Group 2: Trading and Adjustments - Post-consolidation, the common shares will continue to trade under the symbol "PBM" on the Nasdaq Capital Market, with a new CUSIP number 74449F407 [2]. - The number of shares and the exercise price of outstanding warrants and other equity instruments will be adjusted proportionately according to their respective terms [3]. Group 3: Shareholder Impact - No fractional shares will be issued; any resulting fractions will be rounded to the nearest whole share [4]. - The consolidation affects all shareholders uniformly, with minor adjustments for fractional shares [4]. - Beneficial holders may experience delays in the reflection of the consolidation in their accounts, depending on their broker's procedures [4][5]. Group 4: Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine-based medicines [6]. - The Company aims to address unmet mental health needs through evidence-based approaches in developing safe and effective treatments [6].